by Jakub Jarolím, Business Intelligence Department
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Sotio Biotech
18/6/2022
May 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Biotech market remains low, and no oncology IPO was completed in last three months
April was the cruelest month for biotech so far and the stocks remain low. However, big pharma companies are still resisting temptation for biotech M&A spree until prices drop further. The IPO market is also dead, with only 12 IPOs completed this year and no oncology IPO in last three months.
Share on social networks